ALTSHULER DAVID
SEC CIK 1550395 · EDGAR
BoughtSold
Companies
| Ticker | Company | Title | Holding | Bought | Sold | Trades | First | Last |
|---|---|---|---|---|---|---|---|---|
| VRTX | Vertex Pharmaceuticals | EVP, CSO, Gbl Research | 34.5K | — | $29.67M | 54 | 2021-11-15 | 2026-01-22 |
Most active insiders at VRTX, 12 months
| # | Insider | Title | Bought | Sold |
|---|---|---|---|---|
| 1 | LEIDEN JEFFREY M | Executive COB, Dir | — | $60.94M |
| 2 | Sachdev Amit | EVP Chief Patient, Ext Af Off | — | $28.38M |
| 3 | Kewalramani Reshma | CEO, Pres, Dir | — | $19.74M |
| 4 | Bozic Carmen | EVP, CMO | — | $11.31M |
| 5 | WAGNER CHARLES F JR | EVP, CO, FO | — | $10.78M |
| 6 | Tatsis Ourania | EVP, Chief Reg, Quality Off | — | $6.51M |
| 7 | McKechnie Duncan | EVP, Chief Commercial Off | — | $5.66M |
| 8 | Biller Jonathan | EVP, CLO | — | $4.08M |
| 9 | Atkinson Edward Morrow III | EVP, Chief Technical Ops. Off | — | $3.60M |
| 10 | Bunnage Mark E. | EVP, CSO | — | $3.00M |
| 18 | ALTSHULER DAVID | EVP, CSO | — | — |
Transactions 54
| X | Filed | Traded | Ticker | Company | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| M | 2026-01-26 | 2026-01-22 | VRTX | Vertex Pharmaceuticals | ALTSHULER DAVID | EVP, CSO | A - Grant | $0.00 | +11.2K | 34.5K | +48% | $0 |
| 2025-05-19 | 2025-05-15 | VRTX | Vertex Pharmaceuticals | ALTSHULER DAVID | EVP, CSO | S - Sale | $424.69 | -52 | 23.3K | -0.2% | -$22.1K | |
| 2025-03-17 | 2025-03-13 | VRTX | Vertex Pharmaceuticals | ALTSHULER DAVID | EVP, CSO | S - Sale | $510.00 | -3,231 | 23.3K | -12% | -$1.65M | |
| 2025-03-12 | 2025-03-10 | VRTX | Vertex Pharmaceuticals | ALTSHULER DAVID | EVP, CSO | S - Sale | $500.00 | -3,231 | 26.5K | -11% | -$1.62M | |
| 2025-03-05 | 2025-03-03 | VRTX | Vertex Pharmaceuticals | ALTSHULER DAVID | EVP, CSO | S - Sale | $490.00 | -3,231 | 29.7K | -10% | -$1.58M | |
| 2025-02-28 | 2025-02-26 | VRTX | Vertex Pharmaceuticals | ALTSHULER DAVID | EVP, CSO | F - Tax | $479.61 | -5,954 | 34.2K | -15% | -$2.86M | |
| 2025-02-28 | 2025-02-27 | VRTX | Vertex Pharmaceuticals | ALTSHULER DAVID | EVP, CSO | S - Sale | $480.00 | -1,272 | 33.0K | -4% | -$610.6K | |
| 2025-02-26 | 2025-02-24 | VRTX | Vertex Pharmaceuticals | ALTSHULER DAVID | EVP, CSO | F - Tax | $483.28 | -3,971 | 41.0K | -9% | -$1.92M | |
| 2025-02-26 | 2025-02-25 | VRTX | Vertex Pharmaceuticals | ALTSHULER DAVID | EVP, CSO | S - Sale | $480.95 | -848 | 40.2K | -2% | -$407.8K | |
| 2025-02-24 | 2025-02-20 | VRTX | Vertex Pharmaceuticals | ALTSHULER DAVID | EVP, CSO | S - Sale | $480.00 | -1,111 | 45.0K | -2% | -$533.3K | |
| 2025-02-19 | 2025-02-14 | VRTX | Vertex Pharmaceuticals | ALTSHULER DAVID | EVP, CSO | F - Tax | $463.46 | -2,293 | 46.1K | -5% | -$1.06M | |
| 2025-02-14 | 2025-02-12 | VRTX | Vertex Pharmaceuticals | ALTSHULER DAVID | EVP, CSO | A - Grant | $0.00 | +5,324 | 48.4K | +12% | $0 | |
| 2025-02-12 | 2025-02-10 | VRTX | Vertex Pharmaceuticals | ALTSHULER DAVID | EVP, CSO | F - Tax | $467.98 | -2,142 | 43.1K | -5% | -$1.00M | |
| M | 2025-02-06 | 2025-02-04 | VRTX | Vertex Pharmaceuticals | ALTSHULER DAVID | EVP, CSO | A - Grant | $0.00 | +19.4K | 45.2K | +75% | $0 |
| 2024-11-19 | 2024-11-15 | VRTX | Vertex Pharmaceuticals | ALTSHULER DAVID | EVP, CSO | S - Sale | $478.56 | -15 | 25.8K | -0.1% | -$7,178 | |
| 2024-05-17 | 2024-05-15 | VRTX | Vertex Pharmaceuticals | ALTSHULER DAVID | EVP, CSO | S - Sale | $430.93 | -54 | 25.8K | -0.2% | -$23.3K | |
| 2024-02-27 | 2024-02-26 | VRTX | Vertex Pharmaceuticals | ALTSHULER DAVID | EVP, CSO, Gbl Research | S - Sale | $425.70 | -4,239 | 25.8K | -14% | -$1.80M | |
| 2024-02-27 | 2024-02-23 | VRTX | Vertex Pharmaceuticals | ALTSHULER DAVID | EVP, CSO, Gbl Research | F - Tax | $431.79 | -3,970 | 30.1K | -12% | -$1.71M | |
| 2024-02-23 | 2024-02-21 | VRTX | Vertex Pharmaceuticals | ALTSHULER DAVID | EVP, CSO, Gbl Research | S - Sale | $421.77 | -3,002 | 34.0K | -8% | -$1.27M | |
| M | 2024-02-21 | 2024-02-16+ | VRTX | Vertex Pharmaceuticals | ALTSHULER DAVID | EVP, CSO, Gbl Research | F - Tax | $422.54 | -6,562 | 43.8K | -13% | -$2.77M |
| 2024-02-21 | 2024-02-20 | VRTX | Vertex Pharmaceuticals | ALTSHULER DAVID | EVP, CSO, Gbl Research | S - Sale | $420.79 | -4,002 | 37.0K | -10% | -$1.68M | |
| 2024-02-13 | 2024-02-12 | VRTX | Vertex Pharmaceuticals | ALTSHULER DAVID | EVP, CSO, Gbl Research | S - Sale | $420.24 | -3,145 | 47.6K | -6% | -$1.32M | |
| 2024-02-13 | 2024-02-09 | VRTX | Vertex Pharmaceuticals | ALTSHULER DAVID | EVP, CSO, Gbl Research | F - Tax | $422.74 | -2,099 | 50.7K | -4% | -$887.3K | |
| M | 2024-02-08 | 2024-02-06+ | VRTX | Vertex Pharmaceuticals | ALTSHULER DAVID | EVP, CSO, Gbl Research | A - Grant | $0.00 | +20.8K | 52.8K | +65% | $0 |
| 2023-11-17 | 2023-11-15 | VRTX | Vertex Pharmaceuticals | ALTSHULER DAVID | EVP, CSO, Gbl Research | S - Sale | $369.92 | -19 | 32.0K | -0.1% | -$7,028 | |
| 2023-08-11 | 2023-08-09 | VRTX | Vertex Pharmaceuticals | ALTSHULER DAVID | EVP, CSO, Gbl Research | S - Sale | $345.51 | -63 | 32.0K | -0.2% | -$21.8K | |
| 2023-02-28 | 2023-02-24 | VRTX | Vertex Pharmaceuticals | ALTSHULER DAVID | EVP, CSO, Gbl Research | F - Tax | $289.12 | -3,970 | 36.3K | -10% | -$1.15M | |
| M | 2023-02-28 | 2023-02-27 | VRTX | Vertex Pharmaceuticals | ALTSHULER DAVID | EVP, CSO, Gbl Research | S - Sale | $287.51 | -4,238 | 32.0K | -12% | -$1.22M |
| M | 2023-02-22 | 2023-02-21 | VRTX | Vertex Pharmaceuticals | ALTSHULER DAVID | EVP, CSO, Gbl Research | S - Sale | $293.77 | -4,002 | 40.2K | -9% | -$1.18M |
| 2023-02-22 | 2023-02-17 | VRTX | Vertex Pharmaceuticals | ALTSHULER DAVID | EVP, CSO, Gbl Research | F - Tax | $292.85 | -3,750 | 44.2K | -8% | -$1.10M | |
| M | 2023-02-16 | 2023-02-14 | VRTX | Vertex Pharmaceuticals | ALTSHULER DAVID | EVP, CSO, Gbl Research | S - Sale | $298.70 | -6,398 | 50.2K | -11% | -$1.91M |
| M | 2023-02-14 | 2023-02-10+ | VRTX | Vertex Pharmaceuticals | ALTSHULER DAVID | EVP, CSO, Gbl Research | F - Tax | $296.82 | -9,451 | 65.2K | -13% | -$2.81M |
| M | 2023-02-14 | 2023-02-13 | VRTX | Vertex Pharmaceuticals | ALTSHULER DAVID | EVP, CSO, Gbl Research | S - Sale | $298.90 | -4,798 | 54.9K | -8% | -$1.43M |
| DM | 2023-02-08 | 2023-02-06 | VRTX | Vertex Pharmaceuticals | ALTSHULER DAVID | EVP, CSO, Gbl Research | S - Sale+OE | $306.00 | -1,304 | 69.9K | -2% | -$399.0K |
| D | 2023-02-08 | 2023-02-06 | VRTX | Vertex Pharmaceuticals | ALTSHULER DAVID | EVP, CSO, Gbl Research | M - OptEx | $187.53 | +1,304 | 69.9K | +2% | +$244.5K |
| M | 2023-02-03 | 2023-02-01 | VRTX | Vertex Pharmaceuticals | ALTSHULER DAVID | EVP, CSO, Gbl Research | A - Grant | $0.00 | +32.6K | 48.5K | +205% | $0 |
| 2022-11-17 | 2022-11-15 | VRTX | Vertex Pharmaceuticals | ALTSHULER DAVID | EVP, CSO, Gbl Research | S - Sale | $308.61 | -34 | 36.1K | -0.1% | -$10.5K | |
| DM | 2022-11-09 | 2022-11-07 | VRTX | Vertex Pharmaceuticals | ALTSHULER DAVID | EVP, CSO, Gbl Research | S - Sale+OE | $303.04 | -1,303 | 36.2K | -3% | -$394.9K |
| D | 2022-11-09 | 2022-11-07 | VRTX | Vertex Pharmaceuticals | ALTSHULER DAVID | EVP, CSO, Gbl Research | M - OptEx | $187.53 | +1,303 | 37.4K | +4% | +$244.4K |
| DM | 2022-08-10 | 2022-08-08 | VRTX | Vertex Pharmaceuticals | ALTSHULER DAVID | EVP, CSO, Gbl Research | S - Sale+OE | $292.54 | -1,304 | 36.5K | -3% | -$381.5K |
| D | 2022-08-10 | 2022-08-08 | VRTX | Vertex Pharmaceuticals | ALTSHULER DAVID | EVP, CSO, Gbl Research | M - OptEx | $187.53 | +1,304 | 37.4K | +4% | +$244.5K |
| DM | 2022-07-21 | 2022-07-19 | VRTX | Vertex Pharmaceuticals | ALTSHULER DAVID | EVP, CSO, Gbl Research | S - Sale+OE | $288.65 | -17.9K | 53.0K | -25% | -$5.16M |
| DM | 2022-07-21 | 2022-07-19 | VRTX | Vertex Pharmaceuticals | ALTSHULER DAVID | EVP, CSO, Gbl Research | M - OptEx | $174.33 | +17.8K | 53.9K | +49% | +$3.10M |
| 2022-02-28 | 2022-02-24 | VRTX | Vertex Pharmaceuticals | ALTSHULER DAVID | EVP, CSO, Gbl Research | F - Tax | $227.86 | -6,038 | 43.6K | -12% | -$1.38M | |
| M | 2022-02-28 | 2022-02-25 | VRTX | Vertex Pharmaceuticals | ALTSHULER DAVID | EVP, CSO, Gbl Research | S - Sale | $230.98 | -7,572 | 42.6K | -15% | -$1.75M |
| 2022-02-22 | 2022-02-17 | VRTX | Vertex Pharmaceuticals | ALTSHULER DAVID | EVP, CSO, Gbl Research | F - Tax | $232.51 | -3,439 | 54.0K | -6% | -$799.6K | |
| M | 2022-02-22 | 2022-02-18 | VRTX | Vertex Pharmaceuticals | ALTSHULER DAVID | EVP, CSO, Gbl Research | S - Sale | $230.97 | -4,312 | 53.0K | -8% | -$995.9K |
| 2022-02-16 | 2022-02-14 | VRTX | Vertex Pharmaceuticals | ALTSHULER DAVID | EVP, CSO, Gbl Research | S - Sale | $232.02 | -2,444 | 57.4K | -4% | -$567.1K | |
| 2022-02-14 | 2022-02-10 | VRTX | Vertex Pharmaceuticals | ALTSHULER DAVID | EVP, CSO, Gbl Research | F - Tax | $237.74 | -3,518 | 62.2K | -5% | -$836.4K | |
| M | 2022-02-14 | 2022-02-11 | VRTX | Vertex Pharmaceuticals | ALTSHULER DAVID | EVP, CSO, Gbl Research | S - Sale | $235.02 | -2,297 | 59.9K | -4% | -$539.8K |
| D | 2022-02-03 | 2022-02-02 | VRTX | Vertex Pharmaceuticals | ALTSHULER DAVID | EVP, CSO, Gbl Research | M - OptEx | $86.52 | +4,660 | 70.4K | +7% | +$403.2K |
| DM | 2022-02-03 | 2022-02-02 | VRTX | Vertex Pharmaceuticals | ALTSHULER DAVID | EVP, CSO, Gbl Research | S - Sale+OE | $251.47 | -4,660 | 69.0K | -6% | -$1.17M |
| DM | 2022-02-03 | 2022-02-01 | VRTX | Vertex Pharmaceuticals | ALTSHULER DAVID | EVP, CSO, Gbl Research | A - Grant | $0.00 | +32.1K | 65.7K | +96% | $0 |
| M | 2021-11-16 | 2021-11-15 | VRTX | Vertex Pharmaceuticals | ALTSHULER DAVID | EVP, CSO, Gbl Research | S - Sale | $187.22 | -34 | 33.6K | -0.1% | -$6,365 |
Purchase Sale Sale after option exercise All abbreviations